Isaac Bentwich | Source
Isaac is the Founder and CEO of Quris. Prior to Quris, Isaac founded and led three bio-AI technology companies, each of which led revolutions in medicine, genomics, agriculture and conservation. Isaac is a physician and entrepreneur with a passion for leading interdisciplinary teams of scientists and technologists to tackle impactful challenges in the intersection between machine-learning and life-sciences; and to leverage and commercialize the resulting solutions. One of the companies that he founded was Rosetta Genomics (NASDAQ:ROSG), which analyzed the human genome. Isaac led the team at Rosetta Genomics in the discovery of hundreds of novel genes, more so than all the universities in the world combined, and delivered novel cancer diagnostics based on these genes. Its subsidiary, Rosetta Green (TASE:RSTG), was acquired by Monsanto for $35M. Under Isaac’s leadership, team members at Rosetta went on to lead artificial intelligence at IBM, Google and Microsoft. Now, at Quris, Isaac and his team are using a similar bio-AI approach to disrupt the drug development process.
-
17 November 2021article
Pharma startup Quris aims to use a ‘patient on a chip’ to target drug deliveryPharma startup Quris aims to use AI, knowledge of the human genome, and a "patient on a chip" to improve drug delivery. -
17 November 2021article
Quris combines AI with ‘patient on a chip’ to speed drug development and reduce animal testing – TechCrunchThe necessity of animal testing is a sad one for the process of drug discovery, but there’s seemingly no good alternative to mice, even though they’re not particularly accurate human analogues. Quris claims to have the first real option in its combination of AI with data from a “p… -
17 November 2021articleSee the 15-slide presentation this AI company used to raise $9 million for its approach to changing how we test the safety of drugsQuris raised $9 million from angel investors to create an artificial intelligence that learns from tiny chips.
- No employment added.